Guidelines recently published by the Federal Trade Commission are a rehash of increasingly hardline litigation positions taken by the agency in recent years regarding dietary supplement advertising, according to three lawyers with Epstein Becker &...

Dietary supplement “structure/function” claims have long been shrouded in regulatory uncertainty, limiting their utilization by companies hoping to validate and differentiate their products.

The Federal Trade Commission on Tuesday announced publication of a guidance that supplants a document issued in 1998, “Dietary Supplements: An Advertising Guide for Industry.” ...

FDA’s determination in recent months that an anti-aging ingredient cannot be lawfully marketed in dietary supplements is already producing adverse business consequences, sources involved in the β-NMN (beta-nicotinamide mononucleotide) market said...

An FDA constituent update and recent warning letters underscore its concerns about CBD in food and beverages, making it unlikely the agency will change its mind soon.

A letter from FDA about an ingredient marketed in dietary supplements sheds light on the agency's interpretation of the drug preclusion clause in the Federal Food, Drug & Cosmetic Act.

FDA’s recently held position is likely to cause disruption to the NMN marketplace and may culminate in a fight—perhaps litigation—between the dietary supplement and drug industries, with the public health agency at the center of the dispute.

The Natural Products Association (NPA) on Tuesday voluntarily dismissed a complaint against FDA regarding NAC (N-acetyl-L-cysteine) products marketed as dietary supplements...

The hemp products company has had a rough go since attracting the attention of a short seller in 2018.